Virongy는 혁신적인 바이러스 연구 및 진단 기술을 개발하는 미국의 바이오기업으로,

바이러스 감염 연구와 치료법 개발을 위한 선도적인 솔루션을 제공합니다.

제품 설명 

Rapid Alpha-Pseudoviruses for Coronavirus Research

제품 번호

 Betacoronavirus Species / Variant / Reporter Gene / Concentration / Size 선택

제품 특징

Rapid alpha-pseudovirus for SARS-CoV-2, SARS-CoV and MERS-CoV

Applications:

• Screening and quantification of anti-coronavirus-neutralizing antibodies
• Anti-coronavirus drug screening
• Quantification of viral mutants’ infectivity
• Identification of host co-factors and restriction factors of coronaviruses

Major advances:

• Faster speed – As fast as 6 hours for the detection of reporter expression for Ha-CoV-2 versus 2-3 days for S protein pseudotyped lentivirus.
• More robust reporter signal – Advantage of the rapid and robust gene expression capacity of alphavirus vector for reporter expression.
• High fidelity in particle structure – Contains all 4 SARS-CoV-2 structural proteins (S, M, E, and N), but no structural proteins from other viruses. In contrast, lenti- and VSV- pseudoviruses contain only the S protein from SARAS-CoV-2, and multiple structural proteins from other viruses, such as HIV-1 Gag and Pol.
• Strong correlation (coefficient value r² = 0.87) with wild-type SARS-CoV-2 in neutralizing antibody assays (Hetrick et al., 2020).

Virongy offers pre-assembled Ha-CoV-2 and other coronaviral alpha-pseudovirus particles.  We also help customers to perform antiviral drug screening and quantification of neutralizing antibodies. For more information, please contact us by email: info@virongy.com

Description:

The hybrid alpha-pseudovirus for SARS-CoV-2 (Ha-CoV-2) is a newly developed SARS-CoV-2 virus-like particle (VLP) that encapsulates an alphavirus-derived RNA genome for rapid report expression (luciferase or GFP) in target cells (Hetrick et al., 2022). Different from commonly used S protein pseudotyped lenti- or vesicular stomatitis virus (VSV)-pseudoviruses, Ha-CoV-2 is assembled with all 4 structural proteins (S, M, N, and E) of SARS-CoV-2, and contains a reporter genome derived from an alphavirus-based vector for rapid (6 hours) and robust expression of reporter genes. The alphavirus vector does not contain any of the structural proteins from the authentic virus and the alpha-pseudovirus particles are single-cycle.

Ha-CoV-2 represents a major technological advancement in the development of SARS-CoV-2 pseudoviruses and serves as a platform for rapid and robust quantification of neutralizing antibodies, viral mutants, and antiviral drugs (Dabbagh et al., 2021; He et al., 2021). Virongy has now expanded its library of rapid alpha-pseudoviruses to other viruses within the coronavirus family.

Example of product Certificate of Analysis

Ha-CoV-2 is intended for Research Use Only and is not for diagnostic or therapeutic purposes or uses in humans or animals.

References

Dabbagh, D., He, S., Hetrick, B., Chilin, L., Andalibi, A., and Wu, Y. (2021). Identification of the SHREK family of proteins as broad-spectrum host antiviral factors. bioRxiv, doi: https://doi.org/10.1101/2021.02.02.429469

He, S., Waheed, A.A., Hetrick, B., Dabbagh, D., Akhrymuk, I.V., Kehn-Hall, K., Freed, E.O., and Wu, Y. (2021). PSGL-1 Inhibits the Incorporation of SARS-CoV and SARS-CoV-2 Spike Glycoproteins into Pseudovirions and Impairs Pseudovirus Attachment and Infectivity. Viruses 13, 46.

Hetrick, B., Chilin, L. D., He, S., Dabbagh, D., Alem, F., Narayanan, A., … & Wu, Y. (2022). Development of a hybrid alphavirus-SARS-CoV-2 pseudovirion for rapid quantification of neutralization antibodies and antiviral drugs. Cell Reports Methods, 100181.

Virongy Biosciences의 모든 제품을 만나 보세요!

Products

Virus-Specific Tools

Psedoviruses

Kits and Reagents

Transduction Enhancers

Cell Lines

Services

Viral Neutralization Assay Services

Peptide Synthesis

Vector Synthesis

Virongy Biosciences - Exclusive Distributor in South Korea "Morebio" 한국 독점 대리점 "모아바이오"